Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Cash & Equivalents (2017 - 2021)

Cogent Biosciences has reported Cash & Equivalents over the past 5 years, most recently at $202.9 million for Q3 2021.

  • Quarterly results put Cash & Equivalents at $202.9 million for Q3 2021, up 56.77% from a year ago — trailing twelve months through Sep 2021 was $202.9 million (up 56.77% YoY), and the annual figure for FY2020 was $242.2 million, up 547.15%.
  • Cash & Equivalents for Q3 2021 was $202.9 million at Cogent Biosciences, down from $218.1 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for COGT hit a ceiling of $242.2 million in Q4 2020 and a floor of $487000.0 in Q1 2020.
  • Median Cash & Equivalents over the past 5 years was $52.9 million (2018), compared with a mean of $90.7 million.
  • Biggest five-year swings in Cash & Equivalents: crashed 99.18% in 2020 and later skyrocketed 47279.67% in 2021.
  • Cogent Biosciences' Cash & Equivalents stood at $28.3 million in 2017, then skyrocketed by 165.38% to $75.0 million in 2018, then tumbled by 50.12% to $37.4 million in 2019, then surged by 547.15% to $242.2 million in 2020, then decreased by 16.23% to $202.9 million in 2021.
  • The last three reported values for Cash & Equivalents were $202.9 million (Q3 2021), $218.1 million (Q2 2021), and $230.7 million (Q1 2021) per Business Quant data.